Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Sep 15, 2024. (Total: 231458Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 8 (of 8 Records)

Query Trace: Colorectal Neoplasms and UGT1A6[original query]
Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk.
Carcinogenesis 2004 Dec 25 (12): 2407-15.
van der Logt E M J, Bergevoet S M, Roelofs H M J, van Hooijdonk Z, te Morsche R H M, Wobbes T, de Kok J B, Nagengast F M, Peters W H
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Feb 11 (3): 1226-36.
Carlini Leslie E, Meropol Neal J, Bever John, Andria Michael L, Hill Todd, Gold Philip, Rogatko Andre, Wang Hao, Blanchard Rebecca
Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006 Jul 4 (7): 894-901.
Samowitz Wade S, Wolff Roger K, Curtin Karen, Sweeney Carol, Ma Khe-Ni, Andersen Kristen, Levin Theodore R, Slattery Martha
Association between polymorphisms in UDP-glucuronosyltransferase 1A6 and 1A7 and colorectal cancer risk.
Asian Pacific journal of cancer prevention : APJCP 2012 13 (5): 2311-4.
Osawa Kayo, Nakarai Chiaki, Akiyama Minami, Hashimoto Ryuta, Tsutou Akimitsu, Takahashi Juro, Takaoka Yuko, Kawamura Shiro, Shimada Etsuji, Tanaka Kenichi, Kozuka Masaya, Yamamoto Masahiro, Kido Yoshia
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
British journal of cancer 2013 Sep 109 (6): 1420-7.
Kim S Y, S Hong Y, K Shim E, Kong S-Y, Shin A, Baek J Y, Jung K
Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry.
Genes, chromosomes & cancer 2014 Jul 53 (7): 568-78.
Scherer Dominique, Koepl Lisel M, Poole Elizabeth M, Balavarca Yesilda, Xiao Liren, Baron John A, Hsu Li, Coghill Anna E, Campbell Peter T, Kleinstein Sarah E, Figueiredo Jane C, Lampe Johanna W, Buck Katharina, Potter John D, Kulmacz Richard J, Jenkins Mark A, Hopper John L, Win Aung K, Newcomb Polly A, Ulrich Cornelia M, Makar Karen
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
British journal of cancer 2017 Aug .
Lévi Francis, Karaboué Abdoulaye, Saffroy Raphaël, Desterke Christophe, Boige Valerie, Smith Denis, Hebbar Mohamed, Innominato Pasquale, Taieb Julien, Carvalho Carlos, Guimbaud Rosine, Focan Christian, Bouchahda Mohamed, Adam René, Ducreux Michel, Milano Gérard, Lemoine Antoinet
Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations.
PloS one 2018 13 (2): e0192223.
Sheth Harsh, Northwood Emma, Ulrich Cornelia M, Scherer Dominique, Elliott Faye, Barrett Jennifer H, Forman David, Wolf C Roland, Smith Gillian, Jackson Michael S, Santibanez-Koref Mauro, Haile Robert, Casey Graham, Jenkins Mark, Win Aung Ko, Hopper John L, Marchand Loic Le, Lindor Noralane M, Thibodeau Stephen N, Potter John D, Burn John, Bishop D Timot
TOP